Cargando…

Dendrimer-based contrast agents for PET imaging

Positron emission tomography (PET) imaging offers physiological and biological information through the in vivo distribution of PET agents for disease diagnosis, therapy monitoring and prognosis evaluation. Due to the unique structural characteristics allowing for facile modification of targeting lig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lingzhou, Shi, Xiangyang, Zhao, Jinhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812586/ https://www.ncbi.nlm.nih.gov/pubmed/29124984 http://dx.doi.org/10.1080/10717544.2017.1399299

Ejemplares similares

Radiolabeled Dendrimers for Nuclear Medicine Applications
por: Zhao, Lingzhou, et al.
Publicado: (2017)

SPECT/CT imaging of chemotherapy-induced tumor apoptosis using (99m)Tc-labeled dendrimer-entrapped gold nanoparticles
por: Xing, Yan, et al.
Publicado: (2018)

Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imaging
por: Wang, Han, et al.
Publicado: (2012)

Radical Dendrimers Based on Biocompatible Oligoethylene Glycol Dendrimers as Contrast Agents for MRI
por: Zhang, Songbai, et al.
Publicado: (2020)

Recent progress in LyP-1-based strategies for targeted imaging and therapy
por: Song, Ningning, et al.
Publicado: (2019)

Dendrimers as Antiamyloid Agents
por: Sorokina, Svetlana A., et al.
Publicado: (2022)

Dendrimer-based nanohybrids in cancer photomedicine
por: Ouyang, Zhijun, et al.
Publicado: (2021)

Self-assembling supramolecular dendrimer nanosystem for PET imaging of tumors
por: Garrigue, Philippe, et al.
Publicado: (2018)

Nanoscale Contrast Agents for Ultrasound Imaging of Musculoskeletal System
por: Tang, Xiaoyi, et al.
Publicado: (2022)

Cyclodextrin-Based Contrast Agents for Medical Imaging
por: Shepelytskyi, Yurii, et al.
Publicado: (2020)

(99m)Tc-Labeled LyP-1 for SPECT Imaging of Triple Negative Breast Cancer
por: Song, Ningning, et al.
Publicado: (2019)

New Ways to Treat Tuberculosis Using Dendrimers as Nanocarriers
por: Mignani, Serge, et al.
Publicado: (2018)

Biogenic Imaging Contrast Agents
por: Dan, Qing, et al.
Publicado: (2023)

Construction of nanomaterials as contrast agents or probes for glioma imaging
por: Zhao, Wei, et al.
Publicado: (2021)

Surface impact on nanoparticle-based magnetic resonance imaging contrast agents
por: Zhang, Weizhong, et al.
Publicado: (2018)

Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches
por: Zhang, Songbai, et al.
Publicado: (2022)

Polyphosphorhydrazone-Based Radical Dendrimers
por: Lloveras, Vega, et al.
Publicado: (2021)

Heterogeneous Dendrimer-Based Catalysts
por: Karakhanov, Eduard, et al.
Publicado: (2022)

[(99m)Tc]Tc-Labeled Plectin-Targeting Peptide as a Novel SPECT Probe for Tumor Imaging
por: Gong, Jiali, et al.
Publicado: (2022)

Contrast agents in dynamic contrast-enhanced magnetic resonance imaging
por: Yan, Yuling, et al.
Publicado: (2017)

Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging
por: Mitchell, Nick, et al.
Publicado: (2013)

Multifunctional dendrimer-based nanoparticles for in vivo MR/CT dual-modal molecular imaging of breast cancer
por: Li, Kangan, et al.
Publicado: (2013)

Rapid contrast-induced encephalopathy after a small dose of contrast agent: illustrative case
por: Zhao, Zhouyang, et al.
Publicado: (2021)

Dendrimer Prodrugs
por: da Silva Santos, Soraya, et al.
Publicado: (2016)

Cytotoxicity of Dendrimers
por: Janaszewska, Anna, et al.
Publicado: (2019)

Which Dendrimer to Attain the Desired Properties? Focus on Phosphorhydrazone Dendrimers†
por: Caminade, Anne-Marie, et al.
Publicado: (2018)

Application of Dendrimer-based Nanoparticles in Glioma Imaging
por: Gonawala, Sunalee, et al.
Publicado: (2017)

A Glimpse into Dendrimers Integration in Cancer Imaging and Theranostics
por: Cruz, Adriana, et al.
Publicado: (2023)

Theranostics and contrast agents for magnetic resonance imaging
por: Jeong, Yohan, et al.
Publicado: (2018)

(64)Cu-Labeled LyP-1-Dendrimer for PET-CT Imaging of Atherosclerotic Plaque
por: Seo, Jai Woong, et al.
Publicado: (2014)

Nanoparticle-Based Paramagnetic Contrast Agents for Magnetic Resonance Imaging
por: Pellico, Juan, et al.
Publicado: (2019)

Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics
por: Ray, Sayoni, et al.
Publicado: (2018)

Melanin-Based Contrast Agents for Biomedical Optoacoustic Imaging and Theranostic Applications
por: Longo, Dario Livio, et al.
Publicado: (2017)

Nanomaterial-based CT contrast agents and their applications in image-guided therapy
por: Jiang, Zeyu, et al.
Publicado: (2023)

(99m)Tc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer
por: Yu, Buhui, et al.
Publicado: (2022)

An experimental phantom study of the effect of gadolinium-based MR contrast agents on PET attenuation coefficients and PET quantification in PET-MR imaging: application to cardiac studies
por: O’ Doherty, Jim, et al.
Publicado: (2017)

Magnetic Nanoparticle-Based High-Performance Positive and Negative Magnetic Resonance Imaging Contrast Agents
por: Tegafaw, Tirusew, et al.
Publicado: (2023)

Pharmacokinetics of Chiral Dendrimer-Triamine-Coordinated Gd-MRI Contrast Agents Evaluated by in Vivo MRI and Estimated by in Vitro QCM
por: Miyake, Yuka, et al.
Publicado: (2015)

Use of contrast agents in oncological imaging: magnetic resonance imaging
por: Morana, Giovanni, et al.
Publicado: (2013)

Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity
por: Mignani, Serge, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j6bmek1a4mttg6vl4g37ojh6v8